

**Discussions with leaders:** *JNM*'s series of interviews with leaders in nuclear and molecular imaging and therapy continues with a conversation with David Collingridge, editor-in-chief of *The Lancet Oncology* and publishing director of *The Lancet* specialty journals. . . . **Page 307**

**The future of theranostics:** Solnes and colleagues provide an overview of already approved theranostic agents and those in development and discuss the potential impacts on cancer and on the field of nuclear medicine. . . . **Page 311**

**<sup>18</sup>F-FDG or bacteria-targeting tracers?** Chen and Dilsizian offer an educational overview of <sup>18</sup>F-FDG PET/CT in cardiovascular device infection diagnosis, the strengths and limitations of bacteria-targeting radiotracers for infection imaging, and the pros and cons of <sup>18</sup>F-FDG versus bacteria-targeting tracers. . . . **Page 319**

**PET/CT and tumor progression in OPSCC:** Wu and colleagues describe development of quantitative imaging features on <sup>18</sup>F-FDG PET and contrast CT imaging for use as markers to assess early response and predict outcomes in oropharyngeal squamous cell carcinoma. . . . **Page 327**

**<sup>18</sup>F-Choline PET/MRI for prostate biopsy:** Davenport and colleagues detail the results of a prospective single-arm clinical trial to determine whether <sup>18</sup>F-choline PET/multiparametric MRI can improve the specificity of multiparametric MRI of the prostate in patients with Gleason  $\geq 3+4$  prostate cancer. . . . **Page 337**

**Interobserver agreement in <sup>18</sup>F-NaF PET/CT:** Zacho and colleagues evaluate interobserver agreement on patient and lesion levels for <sup>18</sup>F-sodium fluoride PET/CT detection of bone metastases in patients with prostate cancer. . . . **Page 344**

**First-line <sup>90</sup>Y for uveal melanoma:** Ponti and colleagues explore the safety and efficacy of <sup>90</sup>Y selective internal radiation therapy as first-line therapy in patients with uveal melanoma metastatic to the liver. . . . **Page 350**

**<sup>18</sup>F-Fluoroglutamine dynamic PET:** Grkovski and colleagues investigate the pharmacokinetic

properties of this radiotracer for imaging tumor glutamine flux and metabolism properties in patients with cancer. . . . **Page 357**

**<sup>18</sup>F-DOPA PET/CT and neuroblastoma:** Piccardo and colleagues evaluate the diagnostic role of <sup>18</sup>F-DOPA PET/CT at the time of staging in children with neuroblastoma, its ability to assess treatment response, and its prognostic value. . . . **Page 367**

**AUC for differentiated thyroid:** Donohoe and members of a cross-disciplinary work group present new appropriate use criteria for nuclear medicine in the evaluation and treatment of differentiated thyroid cancer. . . . **Page 375**

**Patient release after <sup>131</sup>I therapy:** Wu and colleagues report on results from a nationwide survey to evaluate whether practices regarding hospital release of differentiated thyroid cancer patients treated with <sup>131</sup>I have changed since publication of NRC Regulatory Issue Summary 2011-01. . . . **Page 397**

**Total-body PSMA PET for bone staging:** Pomykala and colleagues determine the relationship between serum prostate-specific antigen levels and the incidence of bone metastases detected by total-body <sup>68</sup>Ga-prostate-specific membrane antigen-11 PET/CT and assess the effect of expanding the imaging field. . . . **Page 405**

**End-of-treatment PET in TB:** Lawal and colleagues explore the impact of findings on end-of-treatment <sup>18</sup>F-FDG PET/CT on tuberculosis relapse in patients treated with a standard regimen of antituberculous treatment for drug-sensitive pulmonary tuberculosis. . . . **Page 412**

**PET and inferior colliculi:** Speck and colleagues use <sup>18</sup>F-FDG PET to evaluate the glucose metabolism of the inferior colliculus and primary auditory cortex in patients with asymmetric hearing loss. . . . **Page 418**

**<sup>18</sup>F-ASEM PET in MCI:** Coughlin and colleagues use this tracer to examine the relationship between the  $\alpha 7$ -nicotinic acetylcholine receptor and Alzheimer disease in elderly controls and in patients with mild cognitive impairment. . . . **Page 423**

**<sup>64</sup>Cu-ATSM as a redox imaging marker:** Floberg and colleagues demonstrate that this <sup>64</sup>Cu-labeled PET tracer, developed for hypoxia imaging, is dependent on cellular redox state, with or without hypoxia. . . . **Page 427**

**<sup>89</sup>Zr-HDL tracer guides CSF1R therapy:** Mason and colleagues propose an <sup>89</sup>Zr-labeled high-density lipoprotein nanotracer as a means of rapidly monitoring response to immunotherapy targeting tumor-associated macrophages. . . . **Page 433**

**CDK4/6 inhibitor for PET:** Ramos and colleagues detail development of an <sup>18</sup>F-labeled cyclin-dependent kinase 4/6 inhibitor for breast cancer imaging. . . . **Page 437**

**Tumor-residualizing GRPR-targeted agents:** Zhang and colleagues present a strategy using irreversible inhibitors of cysteine cathepsins as trapping agents to increase tumor retention of agonistic and antagonistic pharmacophores targeting the gastrin-releasing peptide receptor. . . . **Page 443**

**Thirty-day total-body PET:** Rosenkrans and Cai provide perspective on the recent completion of development of total-body PET scanners and discuss a related article in this issue of *JNM*. . . . **Page 451**

**30-day <sup>89</sup>Zr-antibody PET:** Berg and colleagues investigate the technical feasibility and utility of the mini-EXPLORER PET for total-body imaging of <sup>89</sup>Zr-labeled antibodies in rhesus monkeys up to 30 days after injection. . . . **Page 453**

**Preclinical PET/CT standardized protocols:** McDougald and colleagues assess the variability of current preclinical PET/CT acquisition/reconstruction protocols across multiple centers and propose protocols for standardization of multicenter data for routine scanning in preclinical PET/CT laboratories. . . . **Page 461**

**Multivendor, multicenter radiomic study:** Pfaehler and colleagues detail the impact of harmonized image reconstruction on feature consistency, using 3D printed phantom inserts reflecting realistic tumor shapes and heterogeneity uptake. . . . **Page 469**